Brayoptus Pharma Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 06-07-2024
- Paid Up Capital ₹ 0.10 M
as on 06-07-2024
- Company Age 10 Year, 6 Months
- Last Filing with ROC 31 Mar 2023
- Revenue 7.91%
(FY 2023)
- Profit 12.10%
(FY 2023)
- Ebitda 0.48%
(FY 2023)
- Net Worth 52.20%
(FY 2023)
- Total Assets 17.55%
(FY 2023)
About Brayoptus Pharma
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Swapnil Jadhav and Karbhari Mithe serve as directors at the Company.
- CIN/LLPIN
U51909PN2014PTC151531
- Company No.
151531
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
23 Jun 2014
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Pune
Industry
Company Details
- Location
Pune, Maharashtra, India
- Telephone
- Email Address
- Website
-
- Social Media-
What products or services does Brayoptus Pharma Private Limited offer?
Brayoptus Pharma Private Limited offers a wide range of products and services, including Pain Relief Spray, Combiflam Pain Relief Spray, Pain Relief Drugs & Pharmaceuticals, Paracetamol Tablets, Combiflam Tablet, Medical Laboratory Instruments, Blood Bank Equipments, Pain Reliever Gel, Combiflam Gel, Infusion Syringes & Supplies.
Who are the key members and board of directors at Brayoptus Pharma?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Karbhari Mithe  | Director | 23-Jun-2014 | Current |
| Swapnil Jadhav | Director | 23-Jun-2014 | Current |
Financial Performance of Brayoptus Pharma.
Brayoptus Pharma Private Limited, for the financial year ended 2023, experienced modest growth in revenue, with a 7.91% increase. The company also saw a substantial improvement in profitability, with a 12.1% increase in profit. The company's net worth Soared by an impressive increase of 52.2%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Brayoptus Pharma?
In 2023, Brayoptus Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
- Organto Natural Food Products LlpActive 2 years 4 months
Swapnil Jadhav and Karbhari Mithe are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Brayoptus Pharma?
Unlock and access historical data on people associated with Brayoptus Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Brayoptus Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Brayoptus Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
